AU2022425559A1 - Compositions and methods for treating huntington's disease - Google Patents

Compositions and methods for treating huntington's disease Download PDF

Info

Publication number
AU2022425559A1
AU2022425559A1 AU2022425559A AU2022425559A AU2022425559A1 AU 2022425559 A1 AU2022425559 A1 AU 2022425559A1 AU 2022425559 A AU2022425559 A AU 2022425559A AU 2022425559 A AU2022425559 A AU 2022425559A AU 2022425559 A1 AU2022425559 A1 AU 2022425559A1
Authority
AU
Australia
Prior art keywords
antibody
seq
clq
level
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022425559A
Other languages
English (en)
Inventor
Ellen CAHIR-MCFARLAND
Ann MONGAN
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of AU2022425559A1 publication Critical patent/AU2022425559A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022425559A 2021-12-30 2022-12-29 Compositions and methods for treating huntington's disease Pending AU2022425559A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163295213P 2021-12-30 2021-12-30
US63/295,213 2021-12-30
US202263349305P 2022-06-06 2022-06-06
US63/349,305 2022-06-06
PCT/US2022/082523 WO2023130001A1 (en) 2021-12-30 2022-12-29 Compositions and methods for treating huntington's disease

Publications (1)

Publication Number Publication Date
AU2022425559A1 true AU2022425559A1 (en) 2024-07-04

Family

ID=87000332

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022425559A Pending AU2022425559A1 (en) 2021-12-30 2022-12-29 Compositions and methods for treating huntington's disease

Country Status (8)

Country Link
US (1) US20250074973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4457244A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503545A (cg-RX-API-DMAC7.html)
KR (1) KR20240126863A (cg-RX-API-DMAC7.html)
AU (1) AU2022425559A1 (cg-RX-API-DMAC7.html)
IL (1) IL313901A (cg-RX-API-DMAC7.html)
MX (1) MX2024008273A (cg-RX-API-DMAC7.html)
WO (1) WO2023130001A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
EP4457244A4 (en) 2026-01-07
EP4457244A1 (en) 2024-11-06
US20250074973A1 (en) 2025-03-06
JP2025503545A (ja) 2025-02-04
IL313901A (en) 2024-08-01
MX2024008273A (es) 2024-07-19
KR20240126863A (ko) 2024-08-21
WO2023130001A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7275223B2 (ja) ヒト化抗補体因子C1q抗体及びその使用
JP7106386B2 (ja) コロニー刺激因子1受容体(csf1r)を結合する抗体によって状態を治療する方法
JP6646100B2 (ja) 抗cxcr3抗体
US20180303936A1 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
TWI564305B (zh) 治療性抗體
JP7617848B2 (ja) ピログルタメートアミロイド-βに対する抗体及びその使用
US20170290913A1 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
ES2738305T3 (es) Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
JP2021514969A (ja) 抗tigit及び抗pd−l1アンタゴニスト抗体による治療のための投薬
AU2019370485B2 (en) Compositions and methods for treating brain injury
IL296130A (en) Anti-complement factor c1q fab fragments and their uses
IL293386A (en) Methods of use of anti-trem2 antibodies
US20250230225A1 (en) Compositions and methods for treating muscular dystrophy
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
US20240034775A1 (en) Compositions and methods for treating epilepsy
WO2022046614A1 (en) Methods for reducing maternal autoantibodies
EP4228696A1 (en) Compositions and methods for treating blood disorders
US20250074973A1 (en) Compositions and methods for treating huntington’s disease
US20250313615A1 (en) Compositions and methods for treating lupus nephritis
CN118525031A (zh) 用于治疗亨廷顿氏病的组合物和方法
HK40114489A (zh) 用於治疗亨廷顿氏病的组合物和方法
TW201400501A (zh) 新穎抗體及其用途